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Abstract
Aims/hypothesis Substantial weight loss in type 2 diabetes
can achieve a return to non-diabetic biochemical status, with-
out the need for medication. The Diabetes Remission Clinical
Trial (DiRECT), a cluster-randomised controlled trial, is test-
ing a structured intervention designed to achieve and sustain
this over 2 years in a primary care setting to determine prac-
ticability for routine clinical practice. This paper reports the
characteristics of the baseline cohort.
Methods People with type 2 diabetes for <6 years with a BMI
of 27–45 kg/m2 were recruited in 49 UK primary care prac-
tices, randomised to either best-practice diabetes care alone or
with an additional evidence-based weight management pro-
gramme (Counterweight-Plus). The co-primary outcomes, at
12 months, are weight loss ≥15 kg and diabetes remission
(HbA1c <48 mmol/mol [6.5%]) without glucose-lowering
therapy for at least 2 months. Outcome assessors are blinded
to group assignment.
Results Of 1510 people invited, 423 (28%) accepted; of whom,
306 (72%)were eligible at screening and gave informed consent.
Seven participants were later found to have been randomised in
error and one withdrew consent, leaving 298 (176 men, 122
women) who will form the intention to treat (ITT) population
for analysis. Mean (SD) age was 54.4 (7.6) years, duration of
diabetes 3.0 (1.7) years, BMI 34.6 (4.4) kg/m2 for all participants
(34.2 (4.2) kg/m2 in men and 35.3 (4.6) kg/m2 in women) and
baseline HbA1c (on treatment) 59.3 (12.7) mmol/mol (7.6%
[1.2%]). The recruitment rate in the intervention and control
groups, and comparisons between the subgroups recruited in
Scotland and England, showed few differences.
Conclusions/interpretation DiRECT has recruited a cohort of
people with type 2 diabetes with characteristics similar to
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those seen in routine practice, indicating potential widespread
applicability. Over 25% of the eligible population wished to
participate in the study, including a high proportion of men, in
line with the prevalence distribution of type 2 diabetes.
Trial registration www.controlled-trials.com/ISRCTN
03267836; date of registration 20 December 2013
Keywords Formula diet . Remission . Type 2 diabetes .
Weight management
Abbreviations
ALT Alanine aminotransferase
AST Aspartate aminotransferase
CVD Cardiovascular disease
DiRECT Diabetes Remission Clinical Trial
GGT γ-Glutamyl transferase
GP General practitioner
ITT Intention to treat
NECS North East Commissioning Support
PCRN Primary Care Research Network
Introduction
In the early years after diagnosis type 2 diabetes has been
shown to be a reversible metabolic condition [1, 2]. Within
10 years of type 2 diabetes diagnosis, about two-thirds of
individuals can return to non-diabetic levels of blood glucose
control after diet-induced weight loss averaging 15 kg [3].
With stable reduced weight, non-diabetic blood glucose con-
trol and changes in the underlying pathophysiological abnor-
malities persist without glucose-lowering medications for at
least 6 months [3]. However, these results have only been
observed in a small number of motivated volunteers attending
a specialist research unit. The practical implications for rou-
tine clinical practice of such diet-induced type 2 diabetes re-
versal urgently need to be established given widening public
interest in this phenomenon.
Bariatric surgery of any kind can reverse metabolic abnor-
malities in about 70% of people with type 2 diabetes [4], with
the likelihood of benefit determined primarily by the extent of
weight loss and duration of diabetes [5, 6]. However, with
conventional dietary advice mean weight loss is only 3–5%
and remission is rare [7]. In the LookAHEAD study, a greater
mean weight loss of 8% at 12 months produced remission of
type 2 diabetes in 11.5% of participants [8]. The present study
was designed to use a more intensive initial ‘total diet replace-
ment’ approach, using a low-energy formula diet with a struc-
tured behaviour change programme for long-term weight loss
maintenance, delivered in a realistic primary care setting. In a
feasibility study, this programme resulted in a mean weight
loss of about 17 kg by 12 weeks, with 40% remaining
>10 kg and 33% >15 kg below baseline weight at 12 months
[9]. Similar figures have been reported for a roll-out of the
Counterweight-Plus programme to 288 individuals in routine
primary care (L. McCombie, N. Brosnahan, H. Ross, A. Bell-
Higgs, L. Govan, M. E. J. Lean, unpublished results). The
Diabetes Remission Clinical Trial (www.controlled-trials.
com/ISRCTN03267836) was designed to answer a series of
linked questions [10]: What proportion of the whole
population with type 2 diabetes would agree to undertake
substantial weight loss? How many of these could achieve
≥15 kg weight loss and return to non-diabetic blood glucose
control off medication (the twin primary endpoints) at 1 year?
What happens to the major pathophysiological factors underly-
ing type 2 diabetes during continued follow up? What are the
psychological consequences of the programme and can out-
comes be predicted by psychometric variables?What proportion
of the intervention group remains non-diabetic after 2 years?
This paper describes the recruitment process, outcomes of re-
cruitment and baseline characteristics of the study participants.
Methods
A cluster-randomised controlled design was employed, with
general practices the unit of randomisation. General practices
representing populations with wide ranges of social and geo-
graphical features across Scotland and in the Tyneside region
of northeast England were invited to participate by the
Primary Care Research Network (PCRN) in Scotland and
North East Commissioning Support (NECS) in England.
Practices known to be research-active were approached first
as the demands of research work by staff would be too great
for many practices.
The research team met with interested practices to discuss
participation details. Following these meetings, willing prac-
tices were then randomised to intervention or control.
Practices randomised to the control group continued to deliver
usual diabetes and weight management as per current clinical
guidelines. Practices randomised to the intervention group
continued to deliver usual guideline-based care in addition to
an evidence-based weight management programme
(Counterweight-Plus). Randomisation was conducted inde-
pendently by the Robertson Centre for Biostatistics,
University of Glasgow, using a minimisation method to main-
tain balance across groups between the two study regions
(Scotland and Tyneside), including a balance of practice list
sizes (n > 5700 or n ≤ 5700).
Within each general practice, all people with type 2 diabe-
tes meeting inclusion and exclusion criteria were identified by
a computerised search of general practitioner (GP) records,
undertaken by PCRN in Scotland and GP practice staff in
Tyneside. Lists generated by the search were reviewed by
GPs and any individuals recognised to be unsuitable to
590 Diabetologia (2018) 61:589–598
approach because of comorbidity or other practical obstacles
to participation were removed.
Inclusion criteria were age 20–65 years, type 2 diabetes of
duration 0–6 years (diagnosis based on two recorded diagnostic
tests using blood glucose and/or HbA1c [HbA1c >48 mmol/mol
(6.5%) on diet alone or HbA1c >43 mmol/mol (6.1%) on
treatment with oral glucose-lowering agents]), and a BMI of
27–45 kg/m2. Potentially eligible individuals were mailed an
invitation to participate with an information sheet and asked
to respond using prepaid reply envelopes. Full details of
methodology have been previously described [10]. A subse-
quent protocol amendment included the provision of a finan-
cial incentive (50 GBP Amazon retail voucher) for those re-
cruited into the control arm. The intervention arm already
provided a desirable incentive ‘in kind’ for participation (sup-
ply of a formula diet and potential substantial weight loss) but
noitacifitnedI
gnineerc
S
dedulcnI
Agreed to participate
(n=423)
Reasons for exclusion:
HbA1c <48 mmol/mol and not on medication (n=34)
Duration of diabetes >6 years (n=28)
Weight loss >5 kg in last 6 months (n=18)
BMI >45 kg/m2 (n=10)
BMI <27 kg/m2 (n=3)
Age >65 years (n=3)
Substance abuse (n=3)
Unable to attend appointments (n=2)
Unable to comply with diet (n=2)
Poor English (n=2)
On antipsychotic medication (n=2)
Heart failure (n=1)
Other medical condition (n=1)
Hospitalisation for depression (n=1)
Participating in another clinical trial (n=1)
Recent cardiac event (n=1)
Recent pancreatitis (n=1)
Advanced renal disease (n=1)
Did not attend baseline appointment (n=1)
Receiving insulin (n=1)
Could not attend baseline before close of recruitment (n=1)
Potentially eligible participants invited to participate
(n=1510)
Declined 
(n=246)
No response
(n=841)
55 GP practices recruited and randomised 
(intervention, n=27; control, n=28)
Scotland 
(n=15)
Tyneside 
(n=8)
Used for recruitment of participants (n=49)
Scotland 
(n=19)
Tyneside 
(n=7)
Control (n=26)Intervention (n=23)
Excluded at 
screening (n=117)
Recruited into trial
(n=306)
Scotland 
(n=86)
Tyneside 
(n=24)
Scotland 
(n=125)
Tyneside
(n=71)
Intervention
(n=157)
Control
(n=149)
Fig. 1 Flowchart of recruitment
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there had been no such incentive for participants in control
practices.
To ascertain whether the individuals volunteering and in-
cludedwere representative of the wider population with type 2
diabetes, defined by the inclusion and exclusion criteria,
anonymised data on sex, height and weight, duration of dia-
betes and index of multiple deprivation were collated for all
who were invited to participate.
Ethics approval for the Diabetes Remission Clinical Trial
(DiRECT) was secured on 24 January 2014. NHS research
and development approvals for participating Health Board areas
in Scotland and Clinical Commissioning Groups in Tyneside
were then secured. All subsequent protocol amendments have
been similarly approved. Written informed consent was secured
from all participants.
Statistical analyses Summary data are presented overall and by
study area (Scotland, Tyneside). Continuous data are summarised
by the mean and SD, and categorical data by frequencies and
percentages. Study areas are compared using Wilcoxon–Mann–
Whitney tests for continuous data and Fisher’s exact tests for
categorical data. Summary data are presented to enable compar-
ison of the DiRECT study population with the wider Scottish
population and with other studies of type 2 diabetes in the
USA, Canada and Europe. Summary data are also reported for
all individuals who were invited to take part in DiRECT and for
whom anonymous baseline data could be obtained for compar-
ison with the recruited study population. At this stage of analysis
of baseline data, the codes have not been broken to reveal which
participants are in which treatment arm and investigators remain
blinded. Baseline data for the treatment arms will be analysed
later, together with the primary outcome data.
Results
Primary care practice recruitment Of the 523 practices that
received an invitation to participate in the study, 74 expressed
interest in participating. Following meetings with the study
team, 55 practices agreed to participate and were randomised
(34 Scotland, 21 Tyneside). The main factor for non-
participation was the potential time commitment required if
allocated to the intervention arm. Four practices allocated to
intervention and two to control were not required for recruit-
ment. Therefore, 49 practices were asked to recruit partici-
pants (Fig. 1), with list sizes varying between 1400 and
30,000 individuals in both urban and rural areas.
Participant recruitment A total of 1510 potentially eligible
people were invited to participate in the study (Fig. 1). Of these,
423 (28%) accepted the invitation. The response was similar in
the control and intervention arms (Table 1). Of thosewhowished
to participate, 28% were excluded at screening. The most
frequent reasons for exclusion were HbA1c <48 mmol/mol
(6.5%) without glucose-lowering medication, duration of type
2 diabetes >6 years and recent weight loss >5 kg (Fig. 1). From
48 practices, 306 participants gave consent and were recruited
into the trial (no participants were recruited at one of the prac-
tices). After the baseline visit, one participant withdrew consent
and seven participants were subsequently considered to have
been randomised in error because their most recent HbA1c
was already in the non-diabetic range without drug treatment.
These eight participants will not be included in the intention to
treat (ITT) population for data analyses, and data are presented
for the remaining 298 participants.
Baseline characteristics The baseline characteristics of the
study population, detailed in Table 2, were similar for partic-
ipants in Scotland and Tyneside. Mean age at recruitment was
54.4 years. Over half of the study population were male
(59%). Mean BMI was slightly higher in women (35.3 kg/
m2) than in men (34.2 kg/m2). Mean (SD) HbA1c was 59.3
(12.7) mmol/mol (7.6% [1.2%]). Mean duration since diagno-
sis of type 2 diabetes was 3 years. Reflecting the ethnic com-
position of Scotland and Tyneside, 98% of participants were
white, with 0.7% Black African, 0.6% South Asian and 0.3%
other. The majority of participants were prescribed glucose-
lowering medications (n = 226, 76%), most as monotherapy
(n = 144, 48%), with metformin most commonly prescribed
(n = 211, 71%). About a quarter of participants were managed
by diet alone, and 82 (28%) were prescribed two or more
glucose-lowering medications, including 63 (21%) receiving
sulfonylureas. Few participants (12%) were current cigarette
smokers and 50% reported never having smoked. Only 26%
of participants reported any current or recent weight manage-
ment activities. Table 3 shows the documented medical histo-
ry of participants at baseline. Twelve per cent of participants
had existing retinopathy. More than half of the study popula-
tion had a history of hypertension and 55% of participants
were prescribed antihypertensive medication, with over 30%
on two or more drugs. The overall prevalence of cardiovascu-
lar disease (CVD; myocardial infarction, angina, stroke,
Table 1 Recruitment response by treatment allocation and study area
Invited (n) Accepted (n) Response (%)
Intervention arm
Scotland 464 130 28
Tyneside 315 85 27
Total 779 215 28
Control arm
Scotland 552 166 30
Tyneside 179 42 23
Total 731 208 28
Total 1510 423 28
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transient ischaemic attack, heart failure, peripheral vascular dis-
ease, revascularisation, atrial fibrillation) was 12%. Forty three
per cent of participants were prescribed six or more drugs and
13% ten or more. The proportion being treated with antidepres-
sant drugs was 23%. Biochemical data at baseline (Table 4)
were as expected among unselected individuals, predominantly
with obesity and within 6 years of type 2 diabetes diagnosis.
Discussion
DiRECT has a realistic or ‘pragmatic’ design to provide in-
formation about the management of type 2 diabetes in a rou-
tine primary care setting in a largely unselected population in
order to maximise transferability of results. Certain inclusion
criteria were applied for recruitment into DiRECT for various
Table 2 Baseline characteris-
tics by study area (ITT
population)
All Scotland Tyneside p value
N 298 197 101
Sex, n (%)
Male 176 (59.1) 118 (59.9) 58 (57.4) 0.710
Female 122 (40.9) 79 (40.1) 43 (42.6)
Age (years) 54.4 (7.6) 55.2 (7.2) 52.8 (8.1) 0.014
Height (cm)
Men 175.9 (7.1) 175.8 (7.0) 176.2 (7.2) 0.711
Women 160.7 (5.2) 160.6 (5.4) 160.8 (4.9) 0.684
Weight (kg)
Men 106.0 (15.8) 105.7 (15.5) 106.5 (16.6) 0.704
Women 91.2 (13.0) 90.8 (13.9) 92.0 (11.4) 0.476
BMI (kg/m2)
All 34.6 (4.4) 34.6 (4.4) 34.8 (4.4) 0.656
Men 34.2 (4.2) 34.2 (4.2) 34.2 (4.4) 0.929
Women 35.3 (4.6) 35.1 (4.8) 35.6 (4.4) 0.548
Waist circumference (cm)a
Men 110.0 (7.1) 110.7 (6.2) 108.6 (8.7) 0.148
Women 101.6 (8.6) 101.7 (9.3) 101.4 (7.1) 0.831
Hip circumference (cm)a
Men 108.6 (5.6) 109.4 (5.6) 107.1 (5.3) 0.066
Women 111.6 (8.0) 111.9 (8.4) 111.0 (7.1) 0.804
Systolic blood pressure (mm/Hg) 134.9 (16.9) 136.8 (16.4) 131.3 (17.2) 0.004
Diastolic blood pressure (mm/Hg) 85.0 (9.5) 85.5 (9.1) 84.1 (10.2) 0.088
Duration of type 2 diabetes (years) 3.0 (1.7) 3.0 (1.7) 2.9 (1.7) 0.710
Pre-trial HbA1c (from GP records)
mmol/mol 61.6 (13.9) 61.4 (14.2) 62.0 (13.4) 0.441
% 7.79 (1.27) 7.76 (1.30) 7.83 (1.23)
Trial measured HbA1c
mmol/mol 59.3 (12.7) 59.6 (13.4) 58.6 (11.2) 0.880
% 7.57 (1.16) 7.61 (1.22) 7.51 (1.03)
Management of type 2 diabetes, n (%)
Diet alone (no drugs) 72 (24.2) 38 (19.3) 34 (33.7) 0.018
1 drug 144 (48.3) 104 (52.8) 40 (39.6)
≥2 drugs 82 (27.5) 55 (27.9) 27 (26.7)
Smoking status, n (%)
Current 35 (11.7) 21 (10.7) 14 (13.9) 0.663
Former 113 (37.9) 77 (39.1) 36 (35.6)
Never 150 (50.3) 99 (50.3) 51 (50.5)
Current/recent engagement in weight
management activities, n (%)
77 (25.8) 62 (31.5) 15 (14.9) 0.002
Reported weekly alcohol intake (units) 5.5 (9.6) 5.5 (10.3) 5.7 (8.0) 0.040
Data are mean (SD) unless otherwise stated
aWaist and hip circumference was only measured when BMI was <35 kg/m2
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practical reasons. An upper BMI limit of 45 kg/m2 was set
because the protocol required a subsample to undergo abdom-
inalmagnetic resonance imaging.An upper age limit of 65 years
was fixed to avoid the greater mortality rates associated with
older people in a study planned to continue for 2 years and to
optimise attendance at study visits given the greater mobility
problems often faced by older people with type 2 diabetes.
Furthermore, individuals were excluded if they had suffered
myocardial infarction or stroke within the 6 months prior to
recruitment because of engagement in other programmes.
Volunteers for clinical research are usually relatively more
health conscious and there can be a risk of attracting unrepre-
sentative ‘concerned but healthy’ individuals. The DiRECT
cohort included, at baseline, 12% with existing retinopathy,
12% with one or more known manifestations of heart disease
and 13% with microalbuminuria indicating nephropathy.
Impaired renal function (eGFR <60) was present in 3%. In
addition to their diabetes, as may be expected, a high proportion
(57%) had known hypertension and 31% were prescribed two
ormore antihypertensivemedications. Polypharmacywas com-
mon, with 43% being prescribed six or more different drugs
daily and 13% prescribed ten or more drugs. Almost a quarter
of the entire cohort was prescribed antidepressant medications,
some of which are associated with weight gain [11]. Thus, the
DiRECT cohort does not appear to include an excess of ‘wor-
ried well’ or unusually healthy people with type 2 diabetes.
DiRECT recruited a substantial proportion of men. This is
encouraging as this is in line with the higher prevalence of
Table 3 Medical history doc-
umented at baseline by study area
(ITT population)
All Scotland Tyneside p value
N 298 197 101
Diabetic retinopathy 35 (11.7) 20 (10.2) 15 (14.9) 0.256
Hypertensiona 169 (56.7) 113 (57.4) 56 (55.4) 0.805
Current antihypertensive medication 163 (54.7) 113 (57.4) 50 (49.5) 0.220
1 drug 69 (23.2) 45 (22.8) 24 (23.8) 0.279
≥2 drugs 94 (31.5) 68 (34.5) 26 (25.7)
Current antidepressant medication 68 (22.8) 44 (22.3) 24 (23.8) 0.773
Total number of prescribed medications
None 6 (2.0) 3 (1.5) 3 (3.0) 0.280
1–2 47 (15.8) 30 (15.2) 17 (16.8)
3–5 116 (38.9) 73 (37.1) 43 (42.6)
6–9 89 (29.9) 59 (29.9) 30 (29.7)
≥10 40 (13.4) 32 (16.2) 8 (7.9)
Clinical CVD
Myocardial infarction 8 (2.7) 7 (3.6) 1 (1.0) 0.273
Angina 8 (2.7) 6 (3.0) 2 (2.0) 0.721
Stroke 7 (2.3) 5 (2.5) 2 (2.0) 1.000
Transient ischaemic attack 7 (2.3) 7 (3.6) 0 (0.0) 0.100
Heart failure 2 (0.7) 2 (1.0) 0 (0.0) 0.550
Peripheral vascular disease 7 (2.3) 5 (2.5) 2 (2.0) 1.000
Previous revascularisation 4 (1.3) 4 (2.0) 0 (0.0) 0.304
Atrial fibrillation 8 (2.7) 7 (3.6) 1 (1.0) 0.273
Any CVD 37 (12.4) 30 (15.2) 7 (6.9) 0.042
Hyperlipidaemiab 67 (22.5) 48 (24.4) 19 (18.8) 0.307
eGFR <60 ml min−1 l.73 m−2 c 9 (3.1) 7 (3.6) 2 (2.1) 0.723
Arthritis 58 (19.5) 39 (19.8) 19 (18.8) 0.878
Osteoporosis 2 (0.7) 2 (1.0) 0 (0.0) 0.550
Epilepsy 2 (0.7) 1 (0.5) 1 (1.0) 1.000
Other 237 (79.5) 147 (74.6) 90 (89.1) 0.004
Data presented as n (%)
a Hypertension is defined as in the National Institute for Health and Care Excellence (NICE) guidelines for type 2
diabetes [25]
b Hyperlipidaemia is defined as in the NICE guidelines for cardiovascular disease [26]
c For eGFR, n = 196 for Scotland, n = 95 for Tyneside and n = 291 for Au (missing data are owing to missing
creatinine values at baseline)
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type 2 diabetes in men [12]. Comparison of the study popula-
tion with available data for those invited to participate in
DiRECT shows an almost identical proportion of men and
women accepting the invitation to participate (Table 5).
Typically, men are less likely to engage in weight manage-
ment programmes [13–15]. However, the potential for health
improvement is a motivator for weight loss in men [16, 17], so
a potential remission of diabetes or improvement in diabetes
status may have encouraged men to participate in DiRECT.
Whether a total diet replacement approach might be more
attractive to men than to women, and other motivational is-
sues, will be explored in interviews with participants and with
healthcare professionals involved in DiRECT.
Recruitment of participants to any study is challenging.
Poor recruitment can result in inadequate study numbers and
underpowered trials [18]. DiRECTwas based in primary care
in order to provide realistic results transferable to routine prac-
tice. Of the invited practices, 14% accepted, reflecting the
relatively small proportion of general practices in the UK that
are research-active.Many of those are at capacity for taking on
new research projects, being busy NHS general practices with
limited availability of doctor and nurse time for research.
There was great interest in DiRECT, but many of the
research-active practices had already committed to research
studies on other topics. Moreover, practice participation re-
quired practices to be able to provide six to ten individuals
who would meet the inclusion criteria; this excluded some
smaller practices. Recruitment to DiRECT was monitored
closely and recruitment methods were refined to include strat-
egies known to maximise recruitment (e.g. reminder letter,
telephone contact and incentive) [18]. It is remarkable that
28% of all invited to participate expressed interest in doing
so, and most of those who initially volunteered participated
(72%). This far exceeds many other trials that recruited using
similar methods [19] and those that recruited by other means
[20, 21]. The study recruited more than the numbers required
to satisfy the a priori power calculation (140 per group) within
the 2 years allocated for recruitment, and recruitment proved
Table 5 Comparison of invited participants with the DiRECT study
population
Invited population DiRECT participants
n 1155a 298
Sex, n (%)
Male 699 (61.3) 176 (59.1)
Female 442 (38.7) 122 (40.9)
Year of birth 1961 (8) 1961 (8)
BMI (kg/m2) 33.5 (6.9) 34.6 (4.4)
Duration of type 2
diabetes (years)
3.5 (3.2) 3.0 (1.7)
Index of Multiple Deprivation quintile, n (%)
Q1 – Most deprived 257 (22.8) 63 (21.4)
Q2 185 (16.4) 52 (17.6)
Q3 226 (20.0) 64 (21.7)
Q4 238 (21.1) 67 (22.7)
Q5 – Least deprived 222 (19.7) 49 (16.6)
Data are mean (SD) unless otherwise stated
a Data available for 1141 invited participants. Missing data for each item:
sex, n = 14 (invited); year of birth, n = 10 (invited); BMI, n = 22 (invited);
duration of diabetes, n = 603 (invited); deprivation, n = 30 (invited = 27;
DiRECT = 3)
Table 4 Baseline biochemis-
try by study area (ITT population) All Scotland Tyneside p value
n (missing) 291 (7) 196 (1) 95 (6)
Total cholesterol (mmol/l) 4.32 (1.19) 4.38 (1.21) 4.19 (1.13) 0.239
HDL-cholesterol (mmol/l) 1.12 (0.28) 1.14 (0.28) 1.08 (0.29) 0.043
Triacylglycerol (mmol/l) 2.00 (1.17) 2.10 (1.27) 1.80 (0.89) 0.034
ALT (U/l) 34.1 (19.4) 34.8 (20.1) 32.7 (17.8) 0.450
AST (U/l) 24.2 (12.8) 24.8 (13.1) 22.8 (12.2) 0.136
GGT (U/l) 52.4 (56.8) 54.5 (62.8) 48.0 (41.7) 0.567
Creatinine (μmol/l) 68.3 (15.1) 70.7 (15.1) 63.3 (13.9) <0.001
eGFR (ml min−1 1.73 m−2) 98.6 (24.7) 94.3 (22.0) 107.5 (27.4) <0.001
n (missing) 292 (6) 196 (1) 96 (5)
Glucose (mmol/l) 9.01 (2.94) 9.30 (2.94) 8.43 (2.85) 0.010
Insulin (mU/ml) 23.50 (14.35) 25.34 (14.58) 19.67 (13.13) <0.001
n (missing) 292 (6) 197 (0) 95 (6)
ACR (mg/mmol)a 2.16 (6.89) 1.71 (6.73) 3.08 (7.16) 0.414
Microalbuminuria, n (%)b 39 (13.4) 18 (9.1) 21 (22.1) 0.003
Data are mean (SD) unless otherwise stated
a Values <0.5 imputed as 0.25
bDefined as ACR ≥3.5 (female) or ACR ≥2.5 (male)
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difficult to halt resulting in modest over-recruitment. The
ready acceptance of a low-energy liquid diet has been ob-
served in all of our previous studies [1, 3, 9].
Triacylglycerol, insulin, fasting glucose and eGFR were
less good in Scottish participants, in keeping with the slightly
greater age and higher waist circumferences. None of these
differences could be considered clinically important. Average
alanine aminotransferase (ALT) and γ-glutamyl transferase
(GGT) levels were higher than the normal reference range.
There were a small number with ALT and GGT raised more
so than aspartate aminotransferase (AST). This will be partly
the result of fatty liver, which is common in this participant
group, but more substantial elevations in GGT without com-
parable ALT elevations suggest that some participants may
have had undisclosed alcohol excess. Of the 12 participants
with GGT >150 at baseline, only one reported very high al-
cohol consumption (72 units per week). In most instances
transaminases were also elevated but there were no other fea-
tures in the baseline data which might account for abnormal
liver function tests. There were minor excesses of high
albumin/creatinine ratio (ACR) in Tyneside, the reasons for
which were not clear although the numbers are small and do
not allow determination of whether such minor albuminuria
was sustained or transient.
The participants can be considered representative of the gen-
eral population of people with short duration type 2 diabetes,
and their characteristics were similar to those of other large
studies of type 2 diabetes (Table 6). Comparison with
LookAHEAD [20] showed similar mean HbA1c (55 mmol/
mol [7.2%]) and BMI (35.9 kg/m2), low prevalence of CVD
(14.1%) and a high proportion of participants never having
smoked (50.2%), although the proportion of male participants
was lower (40%) and the population slightly older. The preva-
lence of CVDwas higher in the ACCORD [21] and PROactive
[22] studies, but this was a specific inclusion criterion for both
those studies. As in DiRECT, both of these studies had high
proportions of male participants and a similar mean BMI.
Median HbA1c was higher in ACCORD and PROactive
(64 mmol/mol [8%]). Importantly, duration of diabetes was
longer in all three of these previous studies, while it was spe-
cifically limited to <6 years in the present study. This duration
was selected in view of the demonstration of duration of type 2
diabetes being a critical factor in achieving remission [3]. Our
study population was, however, very representative of all peo-
ple with type 2 diabetes in Scotland, in whom the mean dura-
tion of diabetes was 9 years [23]. A greater number of medica-
tions were prescribed to the Scottish than to the Tyneside par-
ticipants, perhaps reflecting variations in the application of the
different clinical guidelines in Scotland [24] and England [25].
A remarkably high proportion of eligible people with type
2 diabetes volunteered to enter DiRECT, including more men
than is usual for weight management trials. The participants
recruited were broadly representative of the unselected gener-
al population of people with up to 6 years’ duration of type 2
diabetes, and the subset in Tyneside were similar to the
Scottish subset. The recruitment rates into the intervention
Table 6 Comparison of DiRECT participant characteristics with those of the wider population of people with type 2 diabetes in Scotland and with
those recruited into other type 2 diabetes studies
DiRECT Scottish population of people
with type 2 diabetes
(2015/2016) [23]
LookAHEAD
[20] (USA)
ACCORD [21]
(USA/Canada)
PROactive
[22] (Europe)
N 298 263,843 5145 10,251 5238
Sex (%)
Male 59.1 57.5 40.6 61.3 66.5
Female 40.9 42.5 59.4 38.7 33.5
Mean age (years) 54.4 66.7 59.0 62.2 61.8
Mean BMI (kg/m2) 34.6 32.0 35.9 32.2 31.0
Duration of type 2 diabetes (years) 3.0 9.3 7.0 10 8
Mean HbA1c
mmol/mol 59.3 59.1 56.0 67.0 63.0
% 7.6 7.6 7.3 8.3 7.9
History of hypertension (%) 56.7 n/a 80.3 n/a 75.6
Antihypertensive medication (%) 54.7 n/a 68.4 85.5 n/a
Smoking status (%)
Current 11.7 n/a 4.4 14.0 13.5
Former 37.9 45.4 44.0 45
Never 50.3 50.2 42.0 n/a
History of CVD (%) 12.4 n/a 14.1 35.0 n/a
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and control arms were almost identical. The results of the
weight management intervention in DiRECT are thus likely
to be widely applicable to people with type 2 diabetes.
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